OptimizeRx Co. (NASDAQ:OPRX) Receives $9.06 Average PT from Analysts

OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $9.06.

OPRX has been the subject of a number of analyst reports. B. Riley lowered their target price on shares of OptimizeRx from $17.00 to $13.00 and set a "buy" rating for the company in a research note on Tuesday, December 24th. JMP Securities reissued a "market outperform" rating and issued a $8.00 price objective on shares of OptimizeRx in a research report on Thursday, February 6th. Royal Bank of Canada restated a "sector perform" rating and set a $6.00 target price (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Barclays lowered their target price on OptimizeRx from $11.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday, November 14th. Finally, Lake Street Capital restated a "buy" rating and set a $11.00 price target on shares of OptimizeRx in a report on Tuesday, December 24th.

Insider Buying and Selling

In other OptimizeRx news, CEO William J. Febbo acquired 20,000 shares of the stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the completion of the acquisition, the chief executive officer now owns 601,253 shares in the company, valued at approximately $3,012,277.53. This represents a 3.44 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds and other institutional investors have recently made changes to their positions in OPRX. SBI Securities Co. Ltd. bought a new stake in OptimizeRx during the 4th quarter worth approximately $25,000. BNP Paribas Financial Markets increased its position in shares of OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company's stock valued at $28,000 after purchasing an additional 2,414 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of OptimizeRx in the 4th quarter worth approximately $51,000. Wells Fargo & Company MN lifted its position in shares of OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after buying an additional 2,797 shares during the last quarter. Finally, Quest Partners LLC grew its stake in shares of OptimizeRx by 15,965.6% during the 3rd quarter. Quest Partners LLC now owns 9,800 shares of the company's stock worth $76,000 after acquiring an additional 9,739 shares during the period. 76.47% of the stock is owned by institutional investors.

OptimizeRx Trading Down 4.1 %

OptimizeRx stock traded down $0.23 during mid-day trading on Friday, hitting $5.33. 42,356 shares of the stock were exchanged, compared to its average volume of 145,585. The firm's fifty day simple moving average is $5.44 and its two-hundred day simple moving average is $6.20. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12 month low of $3.78 and a 12 month high of $16.65. The stock has a market capitalization of $98.22 million, a price-to-earnings ratio of -4.00 and a beta of 1.38.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.